一种新型血清肿瘤标志物CA 242在胰腺癌中的临床评估
Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
作者信息
Pasanen P A, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E
机构信息
Department of Surgery, Kuopio University Hospital, Finland.
出版信息
Br J Cancer. 1992 May;65(5):731-4. doi: 10.1038/bjc.1992.154.
The aim of this study was to evaluate the new monoclonal tumour marker CA 242 in the diagnosis of pancreatic carcinoma and to compare it with the established markers CA 50 and CEA. Serum concentrations were determined in 113 patients with jaundice, in 20 patients with laboratory values suggesting cholestasis, and in 60 patients with a suspicion to have chronic pancreatitis. Twenty-four of these 193 patients had pancreatic carcinoma and two patients had carcinoma of papilla of Vater. The sensitivities of CA 242, CA 50 and CEA were 80.7%, 96.1%, and 92.3%, respectively. The specificities were 79.0%, 58.0%, and 59.2%. The sensitivities of combinations of CA 50 and CEA with CA 242 did not exceed the sensitivity of CA 50 alone. The specificity of CA 242 was improved by combining it with CEA (92.2%). The serum marker CA 242 seems to be less sensitive than CEA and CA 50 in the detection of pancreatic carcinoma, but it may prove useful because of its high specificity.
本研究的目的是评估新型单克隆肿瘤标志物CA 242在胰腺癌诊断中的价值，并将其与已确立的标志物CA 50和癌胚抗原（CEA）进行比较。测定了113例黄疸患者、20例实验室检查提示胆汁淤积的患者以及60例疑似慢性胰腺炎患者的血清浓度。这193例患者中，24例患有胰腺癌，2例患有 Vater 乳头癌。CA 242、CA 50和CEA的敏感性分别为80.7%、96.1%和92.3%。特异性分别为79.0%、58.0%和59.2%。CA 50和CEA与CA 242联合检测的敏感性未超过单独检测CA 50的敏感性。CA 242与CEA联合检测可提高其特异性（92.2%）。血清标志物CA 242在检测胰腺癌方面似乎不如CEA和CA 50敏感，但因其高特异性可能具有一定价值。
Zotero 插件